Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Hepatitis C

  Free Subscription


Articles published in J Med Virol

Retrieve available abstracts of 135 articles:
HTML format



Single Articles


    May 2020
  1. WAHID B, Shami K, Joiya SA, Ozuyar SEG, et al
    Comparing the risk of hypothyroidism in HCV patients treated with different DAA drugs combinations (sofosbuvir + interferon + ribavirin and sofosbuvir + daclatasvir + ribavirin).
    J Med Virol. 2020 May 17. doi: 10.1002/jmv.25931.
    PubMed     Abstract available


  2. WATANABE T, Tokumoto Y, Joko K, Michitaka K, et al
    Sex difference in the development of hepatocellular carcinoma after direct-acting antiviral therapy in patients with HCV infection.
    J Med Virol. 2020 May 6. doi: 10.1002/jmv.25984.
    PubMed     Abstract available


    April 2020
  3. JAMIL Z, Waheed Y, Ahsan O, Najmi MH, et al
    Familial Clustering of Hepatitis C Virus in Pakistani Population.
    J Med Virol. 2020 Apr 22. doi: 10.1002/jmv.25926.
    PubMed     Abstract available


    March 2020
  4. JAMSHIDI S, Bokharaei-Salim F, Esghaei M, Bastani MN, et al
    Occult HCV and Occult HBV Co-infection in Iranian Human Immunodeficiency Virus-Infected Individuals.
    J Med Virol. 2020 Mar 31. doi: 10.1002/jmv.25808.
    PubMed     Abstract available


  5. MARGUSINO-FRAMINAN L, Perez EB, Cid-Silva P, Rodriguez-Sotelo A, et al
    Effectiveness and Safety of Direct-Acting Antivirals in Hepatitis C Infected Patients with Mental Disorders: Results in Real Clinical Practice.
    J Med Virol. 2020 Mar 17. doi: 10.1002/jmv.25772.
    PubMed     Abstract available


  6. MUSHTAQ S, Mansoor A, Umar M, Khan A, et al
    Direct-acting antiviral agents in the treatment of chronic Hepatitis C - Real-life experience from clinical practices in Pakistan.
    J Med Virol. 2020 Mar 4. doi: 10.1002/jmv.25745.
    PubMed     Abstract available


    February 2020
  7. LU C, Feng Y, Sun X, Li N, et al
    Tree Shrew Bone Marrow-Derived Mesenchymal Stem Cells Express CD81, OCLN, and miR-122, Facilitating the Entire Hepatitis C Virus Life Cycle.
    J Med Virol. 2020 Feb 13. doi: 10.1002/jmv.25710.
    PubMed     Abstract available


    December 2019
  8. FUCHS M, Monto A, Brau N, Charafeddine M, et al
    Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin for Chronic HCV Infection in US Veterans with Psychiatric Disorders.
    J Med Virol. 2019 Dec 12. doi: 10.1002/jmv.25655.
    PubMed     Abstract available


    November 2019
  9. OMRAN NM, El-Sherbini SM, Hegazy O, Elshaarawy AA, et al
    Crosstalk between miR-215 and Epithelial-Mesenchymal Transition (EMT) specific markers (E- and N-cadherin) in different stages of chronic HCV Infection.
    J Med Virol. 2019 Nov 26. doi: 10.1002/jmv.25637.
    PubMed     Abstract available


  10. DEL-RIOS NHA, de Araujo LA, Martins RMB, Guimaraes RA, et al
    Molecular and Epidemiological Aspects of Hepatitis C Virus Infection Among Crack Cocaine Users.
    J Med Virol. 2019 Nov 20. doi: 10.1002/jmv.25632.
    PubMed     Abstract available


    October 2019
  11. GRABARCZYK P, Kubicka-Russel D, Kopacz A, Liszewski G, et al
    Seronegative hepatitis C virus (HCV) infection in Polish blood donors - virological characteristics of index donations and follow-up observations.
    J Med Virol. 2019 Oct 31. doi: 10.1002/jmv.25617.
    PubMed     Abstract available


  12. MAHMUD S, Chemaitelly HS, Kouyoumjian SP, Kanaani ZA, et al
    Key associations for hepatitis C virus genotypes in the Middle East and North Africa.
    J Med Virol. 2019 Oct 30. doi: 10.1002/jmv.25614.
    PubMed     Abstract available


  13. TSAI TC, Deng ST, Hsu CW
    The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan.
    J Med Virol. 2019 Oct 10. doi: 10.1002/jmv.25605.
    PubMed     Abstract available


  14. SAITO Y, Imamura M, Uchida T, Osawa M, et al
    Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
    J Med Virol. 2019 Oct 4. doi: 10.1002/jmv.25602.
    PubMed     Abstract available


    September 2019
  15. BIN WAHID S, Ain QU, Quraishi A, Wahid B, et al
    Clinical correlation of liver function tests with suppression of cytokine signaling (SOCS1) gene expression in HCV infected patients: a real-world clinical experience.
    J Med Virol. 2019 Sep 19. doi: 10.1002/jmv.25596.
    PubMed     Abstract available


    August 2019
  16. JANG ES, Kim KA, Kim YS, Kim IH, et al
    Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: an emphasis on the pretreatment NS5A resistance-associated substitution test.
    J Med Virol. 2019 Aug 26. doi: 10.1002/jmv.25575.
    PubMed     Abstract available


  17. GHAZY AA, Osman EM, Rashwan EA, Gaballah AH, et al
    Relation between micro RNA-21, Transforming Growth Factor Beta and response to treatment among Chronic Hepatitis C Patients.
    J Med Virol. 2019 Aug 1. doi: 10.1002/jmv.25559.
    PubMed     Abstract available


    July 2019
  18. WAHID B
    Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patient previously treated for Tuberculosis.
    J Med Virol. 2019 Jul 26. doi: 10.1002/jmv.25557.
    PubMed     Abstract available


  19. MACKEN L, Gelson W, Priest M, Abouda G, et al
    Efficacy of direct acting antivirals: UK real world data from a well characterised predominantly cirrhotic HCV cohort.
    J Med Virol. 2019 Jul 22. doi: 10.1002/jmv.25552.
    PubMed     Abstract available


  20. MARTINEZ AP, Garcia G, Ridruejo E, Culasso AC, et al
    Hepatitis C Virus Genotype 1 Infection: Prevalence of NS5A and NS5B Resistance-Associated Substitutions in Naive Patients from Argentina.
    J Med Virol. 2019 Jul 5. doi: 10.1002/jmv.25536.
    PubMed     Abstract available


    June 2019
  21. TADA T, Toyoda H, Yasuda S, Miyake N, et al
    Natural history of liver-related disease in patients with chronic hepatitis C virus infection: an analysis using a Markov chain model.
    J Med Virol. 2019 Jun 29. doi: 10.1002/jmv.25533.
    PubMed     Abstract available


  22. HUANG J, Xu R, Wang M, Liao Q, et al
    Association of HLA-DQB1*03:01 and DRB1*11:01 with spontaneous clearance of hepatitis C virus in Chinese Li ethnicity, an ethnic group genetically distinct from Chinese Han ethnicity and infected with unique HCV subtype.
    J Med Virol. 2019 Jun 29. doi: 10.1002/jmv.25531.
    PubMed     Abstract available


    April 2019
  23. EL KASSAS M, Alboraie M, Omar H, El Latif YA, et al
    High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4: Real world results.
    J Med Virol. 2019 Apr 5. doi: 10.1002/jmv.25478.
    PubMed     Abstract available


  24. ZAYED SA, Zahran NM, Khorshied MM, Abdel-Aziz AO, et al
    Genetic variations in death receptor domain 4 (DR4) gene and the susceptibility to hepatitis C related hepatocellular carcinoma.
    J Med Virol. 2019 Apr 4. doi: 10.1002/jmv.25476.
    PubMed     Abstract available


    March 2019
  25. HUANG R, Rao H, Xie Q, Gao Z, et al
    Comparison of Efficacy of Sofosbuvir plus Ribavirin in Chinese Patients with Genotype 3a or 3b HCV Infection.
    J Med Virol. 2019 Mar 12. doi: 10.1002/jmv.25454.
    PubMed     Abstract available


  26. POORDAD F, Bennett M, Sepe TE, Cohen E, et al
    Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with HCV genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
    J Med Virol. 2019 Mar 6. doi: 10.1002/jmv.25448.
    PubMed     Abstract available


    February 2019
  27. HETTA HF, Zahran AM, Mansor SG, Abdel-Malek MO, et al
    Frequency and Implications of Myeloid Derived Suppressor Cells and Lymphocyte Subsets in Egyptian Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma.
    J Med Virol. 2019 Feb 13. doi: 10.1002/jmv.25428.
    PubMed     Abstract available


  28. GHASEMI A, Zadsar M, Shaiegan M, Samiei S, et al
    Human platelet antigens polymorphisms; Association to the development of liver fibrosis in patients with chronic hepatitis C.
    J Med Virol. 2019 Feb 6. doi: 10.1002/jmv.25423.
    PubMed     Abstract available


    January 2019
  29. KWON JH, Yoo SH, Nam SW, Kim HY, et al
    Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea.
    J Med Virol. 2019 Jan 29. doi: 10.1002/jmv.25412.
    PubMed     Abstract available


  30. KWEON OJ, Lim YK, Kim HR, Kim TH, et al
    Analytical Performance of Newly Developed Rapid Point-of-Care Test for the Simultaneous Detection of Hepatitis A, B, and C Viruses in Serum Samples.
    J Med Virol. 2019 Jan 22. doi: 10.1002/jmv.25405.
    PubMed     Abstract available


  31. ZHU XB, Zhuo LY, Yue M, Liu M, et al
    Genetic variants in IFIH1 and DDX58 influence HCV clearance in Chinese Han Population.
    J Med Virol. 2019 Jan 11. doi: 10.1002/jmv.25398.
    PubMed     Abstract available


    December 2018
  32. BAVARO DF, Saracino A, Fiordelisi D, Bruno G, et al
    Influence of HLA-B18 on liver fibrosis progression in a cohort of HIV/HCV co-infected individuals.
    J Med Virol. 2018 Dec 22. doi: 10.1002/jmv.25385.
    PubMed     Abstract available


  33. YOSRY A, Gamal Eldeen H, Medhat E, Mehrez M, et al
    Ef fi cacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience.
    J Med Virol. 2018 Dec 14. doi: 10.1002/jmv.25362.
    PubMed     Abstract available


    November 2018
  34. KHAN AJ, Saraswat VA, Ranjan P, Parmar D, et al
    Polymorphism in IFNL3/IL28B gene and risk to non-cirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy.
    J Med Virol. 2018 Nov 15. doi: 10.1002/jmv.25359.
    PubMed     Abstract available


  35. NAGAOKI Y, Imamura M, Nisihda Y, Daijo K, et al
    The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma; comparison with interferon-based therapy.
    J Med Virol. 2018 Nov 1. doi: 10.1002/jmv.25352.
    PubMed     Abstract available


  36. DA COSTA MARQUES BORGES LF, Zalis MG, Santoro-Lopes G, Varella RB, et al
    Hepatitis C virus (HCV) genotypes in hemodialysis patients in Angola.
    J Med Virol. 2018 Nov 1. doi: 10.1002/jmv.25354.
    PubMed     Abstract available


    October 2018
  37. YANG H, Wu J, Yuan Y, Huang W, et al
    Retrospectively Seroprevalence Study on Anti-HEV-IgG antibody in patients with chronic hepatitis or liver cirrhosis in a Chinese teaching hospital.
    J Med Virol. 2018 Oct 11. doi: 10.1002/jmv.25335.
    PubMed     Abstract available


    September 2018
  38. EL HADI H, Benani A, Qmichou Z, Lazar F, et al
    Development and Validation of an RT-qPCR Assay for Rapid Detection and Quantification of Hepatitis C Virus RNA for Routine Testing in Moroccan Clinical Specimens.
    J Med Virol. 2018 Sep 29. doi: 10.1002/jmv.25326.
    PubMed     Abstract available


  39. WAHID B, Waqar M, Rasool N, Wasim M, et al
    Prevalence of TSH dysfunction among sofosbuvir-treated HCV infected patients: a real-world clinical experience.
    J Med Virol. 2018 Sep 19. doi: 10.1002/jmv.25319.
    PubMed     Abstract available


  40. PENG H, Zhang L, Feng Y, Tang H, et al
    A cross-sectional serum investigation of a clustering HCV infection in Southwest China.
    J Med Virol. 2018 Sep 11. doi: 10.1002/jmv.25315.
    PubMed     Abstract available


  41. KHOSRAVI A, Karimi-Sari H, Abedi-Andani M, Behnava B, et al
    Acute Changes in Cardiac Function by Direct-acting Antiviral Therapy for Hepatitis C Infected Thalassemia Patients.
    J Med Virol. 2018 Sep 11. doi: 10.1002/jmv.25314.
    PubMed     Abstract available


  42. GUOPING D, Xiaoshan L, Musa TH, Yu J, et al
    The Nationwide Distribution and Trends of Hepatitis C Virus Genotypes in Mainland China.
    J Med Virol. 2018 Sep 7. doi: 10.1002/jmv.25311.
    PubMed     Abstract available


  43. SASAKI R, Meyer K, Moriyama M, Kato N, et al
    Rapid hepatitis C virus clearance by antivirals correlates with immune status of infected patients.
    J Med Virol. 2018 Sep 7. doi: 10.1002/jmv.25310.
    PubMed     Abstract available


  44. LI Y, Zeng Y, Zeng G, Li J, et al
    The Effects of Direct-Acting Antiviral Agents on the Frequency of Myeloid-Derived Suppressor Cells and Natural Killer Cells in Patients with Chronic Hepatitis C.
    J Med Virol. 2018 Sep 1. doi: 10.1002/jmv.25302.
    PubMed     Abstract available


    August 2018
  45. ELBAZ T, Abdo M, Omar H, Hassan EA, et al
    Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection.
    J Med Virol. 2018 Aug 23. doi: 10.1002/jmv.25287.
    PubMed     Abstract available


  46. JORDIER F, Deligny ML, Barre R, Robert C, et al
    Human pegivirus (HPgV) isolates characterized by deep sequencing from HCV- and HIV-RNA positive blood donations, France.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25290.
    PubMed     Abstract available


  47. EL-HEFNY MA, Fouad SA, Hussein TD, Abdel-Hameed R, et al
    Circulating miRNAs as predictive biomarkers for liver disease progression of chronic hepatitis C (genotype-4) Egyptian patients.
    J Med Virol. 2018 Aug 22. doi: 10.1002/jmv.25294.
    PubMed     Abstract available


  48. AKUTA N, Sezaki H, Suzuki F, Fujiyama S, et al
    Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-acting antivirals regimens.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25278.
    PubMed     Abstract available


  49. KAHYESH-ESFANDIARY R, Sadigh ZA, Esghaei M, Bastani MN, et al
    Detection of HCV Genome in Peripheral Blood Mononuclear Cells of Iranian Seropositive and HCV RNA negative in Plasma of Patients with Beta-thalassemia Major: Occult HCV Infection.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25279.
    PubMed     Abstract available


  50. LU T, Han Y, Zhang R, Zhang K, et al
    Quantitative detection of hepatitis C virus RNA in urine of patients with chronic hepatitis C using a novel real-time PCR assay.
    J Med Virol. 2018 Aug 9. doi: 10.1002/jmv.25280.
    PubMed     Abstract available


  51. PRAKASH S, Shukla S, Ramakrishna V, Jain A, et al
    Distribution of Hepatitis C Genotypes in Uttar Pradesh, India; Rare Genotype 4 Detected.
    J Med Virol. 2018 Aug 7. doi: 10.1002/jmv.25277.
    PubMed     Abstract available


    July 2018
  52. MORIO K, Imamura M, Kawakami Y, Nakamura Y, et al
    Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C.
    J Med Virol. 2018 Jul 17. doi: 10.1002/jmv.25267.
    PubMed     Abstract available


  53. HASHEM M, Zaghla H, Zakaria Z, Allam WR, et al
    High spontaneous clearance of symptomatic iatrogenic acute hepatitis C genotype 4 infection.
    J Med Virol. 2018 Jul 16. doi: 10.1002/jmv.25270.
    PubMed     Abstract available


  54. ZHAO N, Zheng W, Wu D, Wang X, et al
    Clinical value of HCcAg levels in monitoring acute hepatitis C spontaneous clearance or treatment-induced clearance.
    J Med Virol. 2018 Jul 11. doi: 10.1002/jmv.25256.
    PubMed     Abstract available


  55. JOGEDA EL, Avi R, Pauskar M, Kallas E, et al
    Association of IFNlambda4 rs12979860 Polymorphism with the Acquisition of HCV and HIV Infections among People Who Inject Drugs.
    J Med Virol. 2018 Jul 10. doi: 10.1002/jmv.25258.
    PubMed     Abstract available


  56. EL BATAE H, Amer I, Kobtan A, Saied SM, et al
    Seroprevalence of hepatitis C virus among the newcomer students, Kafrelsheikh University, Egypt.
    J Med Virol. 2018 Jul 7. doi: 10.1002/jmv.25249.
    PubMed     Abstract available


    June 2018
  57. DEGEFA B, Gebreeyesus T, Gebremedhin Z, Melkamu G, et al
    Prevalence of hepatitis B virus, hepatitis C virus and human immunodeficiency virus among blood donors of Mekelle blood bank, Northern Ethiopia: A three year retrospective study.
    J Med Virol. 2018 Jun 15. doi: 10.1002/jmv.25248.
    PubMed     Abstract available


  58. WAKED I, Esmat G, Fouad R, Allam N, et al
    Change in hepatic profile in hepatitis C virus genotype 4 patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: a subanalysis of the AGATE-II study.
    J Med Virol. 2018 Jun 13. doi: 10.1002/jmv.25243.
    PubMed     Abstract available


    May 2018
  59. MARYAM M, Idrees M
    Study of promoter hypomethylation profiles of RAS oncogenes in Hepatocellular Carcinoma derived from Hepatitis C virus genotype 3a in Pakistani population.
    J Med Virol. 2018 May 9. doi: 10.1002/jmv.25221.
    PubMed     Abstract available


  60. ALEM SA, Said M, Anwar I, Abdellatif Z, et al
    Improvement of LSM, ARFI measurements and non-invasive fibrosis markers after DAAs for HCV G4 recurrence post living donor liver transplantation: Egyptian cohort.
    J Med Virol. 2018 May 2. doi: 10.1002/jmv.25210.
    PubMed     Abstract available


  61. DE DIEU LONGO J, Bouassa RM, Simaleko MM, Kouabosso A, et al
    Usefulness of simultaneous screening for HIV- and HCV- specific antibodies and HBsAg by capillary-based multiplex rapid diagnostic test to strengthen linkage-to-care in sub-Saharan patients attending sexually transmitted infections clinic.
    J Med Virol. 2018 May 2. doi: 10.1002/jmv.25209.
    PubMed     Abstract available


    April 2018
  62. Z M, H K, E M, N B, et al
    Indeterminate genotypes of hepatitis C virus by the Abbott RealTime HCV Genotype II assay in Morocco. About 8 cases resolved by a sequencing method.
    J Med Virol. 2018 Apr 16. doi: 10.1002/jmv.25191.
    PubMed     Abstract available


  63. VISCO-COMANDINI U, Lapa D, Lionetti R, Taibi C, et al
    Significance of detectable HCV RNA below the limit of quantification in patients treated with DAAs using standard and ultrasensitive protocols.
    J Med Virol. 2018 Apr 3. doi: 10.1002/jmv.25084.
    PubMed     Abstract available


  64. YANG R, Gao N, Chang Q, Meng X, et al
    The role of IDO, IL-10 and TGF-beta in the HCV-associated chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.
    J Med Virol. 2018 Apr 3. doi: 10.1002/jmv.25083.
    PubMed     Abstract available


    March 2018
  65. MARASCIO N, Pavia G, Romeo I, Talarico C, et al
    Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling.
    J Med Virol. 2018 Mar 25. doi: 10.1002/jmv.25073.
    PubMed     Abstract available


  66. DENG H, Deng X, Liu Y, Xu Y, et al
    Naturally occurring antiviral drug resistance in HIV patients who are mono-infected or co-infected with HBV or HCV in China.
    J Med Virol. 2018 Mar 24. doi: 10.1002/jmv.25078.
    PubMed     Abstract available


  67. ANTONIO UL, Alicia OM, Antonio MJ, Elena GM, et al
    Presence of rare hepatitis C virus subtypes, 2j, 2k and 2r, in Mexico City as identified by sequencing.
    J Med Virol. 2018 Mar 6. doi: 10.1002/jmv.25070.
    PubMed     Abstract available


    February 2018
  68. CORDIE A, Salama A, El-Sharkawy M, El-Nahaas SM, et al
    Comparing the efficiency of Fib-4, Egy-score, APRI and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C.
    J Med Virol. 2018 Feb 24. doi: 10.1002/jmv.25064.
    PubMed     Abstract available


  69. SHOUSHA HI, Abdelaziz RA, Azab SM, Khairy M, et al
    Effect of Treatment with Direct Acting Antivirals on Body Mass Index and Hepatic Steatosis in Chronic Hepatitis C.
    J Med Virol. 2018 Feb 22. doi: 10.1002/jmv.25062.
    PubMed     Abstract available


  70. RAN M, Huang J, Liang H, Jiang J, et al
    Alcohol attenuates anti-HCV function of IFN-lambda1 through up-regulation of PLASy expression in human hepatic cells.
    J Med Virol. 2018 Feb 15. doi: 10.1002/jmv.25053.
    PubMed     Abstract available


  71. OGATA F, Akuta N, Kobayashi M, Fujiyama S, et al
    Amino Acid Substitutions in the Hepatitis C Virus Core Region Predict Hepatocarcinogenesis Following Eradication of HCV RNA by All-Oral Direct-Acting Antiviral Regimens.
    J Med Virol. 2018 Feb 10. doi: 10.1002/jmv.25047.
    PubMed     Abstract available


  72. GRANDAL M, Pernas B, Tabernilla A, Marino A, et al
    Prevalence of NS5A Resistance Associated Substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on Current Therapeutic Strategies.
    J Med Virol. 2018 Feb 10. doi: 10.1002/jmv.25048.
    PubMed     Abstract available


    January 2018
  73. SUN LJ, Yu JW, Shi YG, Zhang XY, et al
    Hepatitis C virus core protein induces dysfunction of liver sinusoidal endothelial cell by down-regulation of silent information regulator 1.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25034.
    PubMed     Abstract available


  74. MOUREZ T, Decroos A, Goria O, Montialoux H, et al
    Misidentification of recombinant hepatitis C virus leading to treatment failure with direct acting antivirals.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25035.
    PubMed     Abstract available


  75. MARCIANO S, Haddad L, Reggiardo MV, Peralta M, et al
    Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: a real world study.
    J Med Virol. 2018 Jan 19. doi: 10.1002/jmv.25033.
    PubMed     Abstract available


  76. MARIO S, Carmine M, Stefania P, Margherita M, et al
    VIROLOGICAL PATTERNS OF HCV PATIENTS WITH FAILURE TO INTERFERON-FREE REGIMENS.
    J Med Virol. 2018 Jan 9. doi: 10.1002/jmv.25022.
    PubMed     Abstract available


  77. GAMIL M, Alboraie M, El-Sayed M, Elsharkawy A, et al
    Novel scores combining AFP with non-invasive markers for prediction of liver fibrosis in chronic hepatitis C patients.
    J Med Virol. 2018 Jan 6. doi: 10.1002/jmv.25026.
    PubMed     Abstract available


  78. OHYA K, Akuta N, Suzuki F, Fujiyama S, et al
    Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2.
    J Med Virol. 2018 Jan 5. doi: 10.1002/jmv.25023.
    PubMed     Abstract available


    December 2017
  79. MATHUR P, Emmanuel B, Sneller M, Zhang X, et al
    Recovery of Hepatitis C Specific T-cell Responses after Rituximab Therapy in Hepatitis C Mixed Cryoglobulinemic Vasculitis.
    J Med Virol. 2017 Dec 13. doi: 10.1002/jmv.25002.
    PubMed     Abstract available


    November 2017
  80. ISHIGAMI M, Hayashi K, Honda T, Kuzuya T, et al
    Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.
    J Med Virol. 2017 Nov 7. doi: 10.1002/jmv.24978.
    PubMed     Abstract available


  81. SU S, Fairley CK, Sasadeusz J, He J, et al
    HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    J Med Virol. 2017 Nov 1. doi: 10.1002/jmv.24988.
    PubMed     Abstract available


    October 2017
  82. GEWAID H, Mesalam AA, Ibrahim AA, Abdel Shafy DN, et al
    Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate.
    J Med Virol. 2017 Oct 24. doi: 10.1002/jmv.24977.
    PubMed     Abstract available


  83. SILVA RAD, de Souza Todao J, Kamitani FL, Benedito Silva AE, et al
    MOLECULAR CHARACTERIZATION OF HEPATITIS C VIRUS IN END-STAGE RENAL DISEASE PATIENTS UNDER HEMODIALYSIS.
    J Med Virol. 2017 Oct 24. doi: 10.1002/jmv.24976.
    PubMed     Abstract available


  84. AL-RADDADI RM, Dashash NA, Alghamdi HA, Al-Raddadi ZM, et al
    Hepatitis C virus infection in Jeddah City, Saudi Arabia: Seroprevalence and knowledge.
    J Med Virol. 2017 Oct 11. doi: 10.1002/jmv.24973.
    PubMed     Abstract available


  85. CARRASCO I, Arias A, Benitez-Gutierrez L, Lledo G, et al
    Baseline NS5A Resistance Associated Substitutions May Impair DAA Response in Real-World Hepatitis C Patients.
    J Med Virol. 2017 Oct 9. doi: 10.1002/jmv.24971.
    PubMed     Abstract available


    September 2017
  86. RAHMAN M, Hossain ME, Afrad MH, Hasan R, et al
    Hepatitis C Virus infections among clients attending an HIV testing and counseling center in Dhaka, Bangladesh.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24955.
    PubMed     Abstract available


  87. CIANCIO A, Bosio R, Bo S, Pellegrini M, et al
    SIGNIFICANT IMPROVEMENT OF GLYCAEMIC CONTROL IN DIABETIC PATIENTS WITH HCV INFECTION RESPONDING TO DIRECT-ACTING ANTIVIRAL AGENTS.
    J Med Virol. 2017 Sep 28. doi: 10.1002/jmv.24954.
    PubMed     Abstract available


  88. OGASAWARA N, Kobayashi M, Akuta N, Kominami Y, et al
    Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
    J Med Virol. 2017 Sep 14. doi: 10.1002/jmv.24950.
    PubMed     Abstract available


  89. AHMED AM, Doheim MF, Mattar OM, Sherif NA, et al
    Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
    J Med Virol. 2017 Sep 11. doi: 10.1002/jmv.24947.
    PubMed     Abstract available


  90. CAVARETTO LDSP, Motta-Castro ARC, Teles SA, de Souza FQ, et al
    Epidemiological and molecular analysis of hepatitis B virus infection in manicurists in Central Brazil.
    J Med Virol. 2017 Sep 8. doi: 10.1002/jmv.24940.
    PubMed     Abstract available


    August 2017
  91. DEHGHANI-DEHEJ F, Sarvari J, Esghaei M, Hosseini SY, et al
    Presence of Different Hepatitis C Virus Genotypes in Plasma and Peripheral Blood Mononuclear Cell Samples of Iranian Patients with HIV Infection.
    J Med Virol. 2017 Aug 28. doi: 10.1002/jmv.24925.
    PubMed     Abstract available


  92. SHEPHERD SJ, McDonald SA, Palmateer NE, Gunson RN, et al
    HCV avidity as a tool for detection of recent HCV infection: sensitivity depends on HCV genotype.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24919.
    PubMed     Abstract available


  93. SCHNELL G, Tripathi R, Krishnan P, Beyer J, et al
    Resistance Characterization of Hepatitis C Virus Genotype 2 from Japanese Patients Treated with Ombitasvir and Paritaprevir/Ritonavir.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24923.
    PubMed     Abstract available


  94. MAHMUD S, Kanaani ZA, Chemaitelly H, Chaabna K, et al
    Hepatitis C Virus Genotypes in the Middle East and North Africa: Distribution, Diversity, and Patterns.
    J Med Virol. 2017 Aug 26. doi: 10.1002/jmv.24921.
    PubMed     Abstract available


  95. YANG T, Chen Q, Li D, Wang T, et al
    High prevalence of syphilis, HBV and HCV co-infection, and low rate of effective vaccination against hepatitis B in HIV-infected patients in West China hospital.
    J Med Virol. 2017 Aug 9. doi: 10.1002/jmv.24912.
    PubMed     Abstract available


    July 2017
  96. WEHMEYER MH, Ingiliz P, Christensen S, Hueppe D, et al
    Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03).
    J Med Virol. 2017 Jul 15. doi: 10.1002/jmv.24903.
    PubMed     Abstract available


  97. LISBOA NETO G, M Malta F, Gomes-Gouvea MS, F Noble C, et al
    CHARACTERIZATION OF CLINICAL PREDICTORS OF NATURALLY OCCURRING NS3/NS4A PROTEASE POLYMORPHISM IN GENOTYPE 1 HEPATITIS C VIRUS MONO AND HIV CO-INFECTED PATIENTS.
    J Med Virol. 2017 Jul 12. doi: 10.1002/jmv.24900.
    PubMed     Abstract available


  98. LU J, Xiang X, Cao Z, Wang W, et al
    Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China.
    J Med Virol. 2017 Jul 3. doi: 10.1002/jmv.24894.
    PubMed     Abstract available


    June 2017
  99. KAN H, Imamura M, Kawakami Y, Daijo K, et al
    Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
    J Med Virol. 2017 Jun 28. doi: 10.1002/jmv.24885.
    PubMed     Abstract available


  100. MOBARAK L, Omran D, Nabeel MM, Zakaria Z, et al
    Fibro markers for prediction of hepatocellular carcinoma in Egyptian patients with chronic liver disease.
    J Med Virol. 2017;89:1062-1068.
    PubMed     Abstract available


    May 2017
  101. SHI X, Jiao B, Chen Y, Li S, et al
    MxA Is A Positive Regulator of Type I IFN Signaling in HCV Infection.
    J Med Virol. 2017 May 31. doi: 10.1002/jmv.24867.
    PubMed     Abstract available


  102. KAR P, Kumar D, Gumma PK, Chowdhury SJ, et al
    Down regulation of TRIF, TLR3 and MAVS in HCV infected liver correlates with the outcome of infection.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24849.
    PubMed     Abstract available


  103. HUDSON B, Walker AJ, Irving WL
    Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24848.
    PubMed     Abstract available


  104. RAZIKY ME, Zayed NA, Baki AA, Mansour SA, et al
    ITPA Gene polymorphism (94C>A) Effects on Ribavirin-Induced Anemia during Therapy in Egyptian Patients with Chronic Hepatitis C.
    J Med Virol. 2017 May 8. doi: 10.1002/jmv.24844.
    PubMed     Abstract available


  105. SCOGNAMIGLIO P, Piselli P, Fusco M, Pisanti FA, et al
    DECLINING UNAWARENESS OF HCV-INFECTION PARALLEL TO DECLINING PREVALENCE IN SOUTHERN ITALY.
    J Med Virol. 2017 May 2. doi: 10.1002/jmv.24840.
    PubMed     Abstract available


    April 2017
  106. DE PASCHALE M, Manco MT, Arpino O, Ricucci V, et al
    Threshold value of LIAISON XL anti-HCV screening assay predicting positive immunoblotting results.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24831.
    PubMed     Abstract available


  107. JIAO X, Fan Z, Chen H, He P, et al
    Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients.
    J Med Virol. 2017 Apr 12. doi: 10.1002/jmv.24829.
    PubMed     Abstract available


    March 2017
  108. MENDIZABAL M, Haddad L, Gallardo PE, Ferrada A, et al
    Ombitasvir/paritaprevir/ritonavir/dasabuvir +/- ribavirin is safe and effective in HCV infected patients in a real-life cohort from Latin America.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24816.
    PubMed     Abstract available


  109. KHALIFA RH, Labib DA, Kamel MA, Shahin RM, et al
    Role of ApoB-516C/T promoter gene polymorphism in the risk of Hepatitis C virus infection in Egyptian patients and in gender susceptibility.
    J Med Virol. 2017 Mar 29. doi: 10.1002/jmv.24815.
    PubMed     Abstract available


  110. HIRAMATSU K, Matsuda H, Nemoto T, Nosaka T, et al
    Identification of novel variants in HLA class II region related to HLA DPB1 expression and disease progression in patients with chronic hepatitis C.
    J Med Virol. 2017 Mar 22. doi: 10.1002/jmv.24814.
    PubMed     Abstract available


  111. JONES M, Cunningham ME, Wing P, DeSilva S, et al
    SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants.
    J Med Virol. 2017 Mar 17. doi: 10.1002/jmv.24809.
    PubMed     Abstract available


    February 2017
  112. FLORES GL, Cruz HM, Marques VA, Villela-Nogueira CA, et al
    Performance of anti-HCV testing in dried blood spots and saliva according to HIV status.
    J Med Virol. 2017 Feb 6. doi: 10.1002/jmv.24777.
    PubMed     Abstract available


  113. WATANABE T, Tokumoto Y, Joko K, Michitaka K, et al
    Predictors of treatment efficacy and ALT non-normalization with sofosbuvir/ribavirin therapy for patients with hepatitis C virus genotype 2.
    J Med Virol. 2017 Feb 6. doi: 10.1002/jmv.24776.
    PubMed     Abstract available


    January 2017
  114. HUNDIE GB, Raj VS, Gebre Michael D, Haagmans BL, et al
    Seroepidemiology of hepatitis B and C virus infections among blood donors in Ethiopia.
    J Med Virol. 2017 Jan 25. doi: 10.1002/jmv.24770.
    PubMed     Abstract available


  115. AKUTA N, Sezaki H, Suzuki F, Fujiyama S, et al
    Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens.
    J Med Virol. 2017 Jan 12. doi: 10.1002/jmv.24767.
    PubMed     Abstract available


  116. GRANDAL M, Pernas B, Marino A, Alvarez H, et al
    Characterization of chronic HCV infection in Northwest Spain: Impact of the treatment strategic plan of the Spanish National Health Service on HCV cure.
    J Med Virol. 2017 Jan 12. doi: 10.1002/jmv.24766.
    PubMed     Abstract available


    December 2016
  117. MURAKAWA M, Asahina Y, Kawai-Kitahata F, Nakagawa M, et al
    Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
    J Med Virol. 2016 Dec 30. doi: 10.1002/jmv.24763.
    PubMed     Abstract available


  118. WANG L, Chen W, WenXi, Feng J, et al
    The utility of enzyme-linked immunosorbent assays to test core antigen in the diagnosis and antiviral therapy management of hepatitis C virus infections.
    J Med Virol. 2016 Dec 13. doi: 10.1002/jmv.24754.
    PubMed     Abstract available


  119. ZHAO N, Liu J, Sun D
    Detection of HCV genotypes 1b and 2a by a reverse transcription loop-mediated isothermal amplification assay.
    J Med Virol. 2016 Dec 9. doi: 10.1002/jmv.24747.
    PubMed     Abstract available


  120. NGOC NB, Okuno Y, Ajiro M, Iida K, et al
    Retinoid derivative Tp80 exhibits anti-hepatitis C virus activity through restoration of GI-GPx expression.
    J Med Virol. 2016 Dec 6. doi: 10.1002/jmv.24739.
    PubMed     Abstract available


    November 2016
  121. ELFIKY AA, Mahdy SM, Elshemey WM
    Quantitative structure-activity relationship and molecular docking revealed a potency of anti-hepatitis C virus drugs against human corona viruses.
    J Med Virol. 2016 Nov 19. doi: 10.1002/jmv.24736.
    PubMed     Abstract available


  122. BODEAU S, Lemouel JP, Diouf M, Duverlie G, et al
    Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA.
    J Med Virol. 2016 Nov 2. doi: 10.1002/jmv.24726.
    PubMed     Abstract available


  123. SALEMI JL, Spooner KK, Mejia de Grubb MC, Aggarwal A, et al
    National trends of hepatitis B and C during pregnancy across sociodemographic, behavioral, and clinical factors, United States, 1998-2011.
    J Med Virol. 2016 Nov 2. doi: 10.1002/jmv.24725.
    PubMed     Abstract available


    October 2016
  124. HUMAYED SM, El-Mekki AA, Mahfouz AA
    Hepatitis C virus infection in south-western Saudi Arabia: Are we still in the plateau phase?
    J Med Virol. 2016 Oct 13. doi: 10.1002/jmv.24712.
    PubMed     Abstract available


    September 2016
  125. TSUKUDA Y, Suda G, Tsunematsu S, Ito J, et al
    Anti-adipogenic and antiviral effects of L-carnitine on hepatitis C virus infection.
    J Med Virol. 2016 Sep 24. doi: 10.1002/jmv.24692.
    PubMed     Abstract available


  126. ROUABHIA S, Chaabna K
    Hepatitis C infection in eastern Algeria: Between statistics and reality.
    J Med Virol. 2016 Sep 14. doi: 10.1002/jmv.24686.
    PubMed     Abstract available


    August 2016
  127. HAYES CN, Chayama K
    Interferon stimulated genes and innate immune activation following infection with hepatitis B and C viruses.
    J Med Virol. 2016 Aug 10. doi: 10.1002/jmv.24659.
    PubMed     Abstract available


    July 2016
  128. REBBANI K, Ababou M, Nadifi S, Kandil M, et al
    Myxovirus resistance 1 gene polymorphisms and outcomes of viral hepatitis B and C infections in Moroccan patients.
    J Med Virol. 2016 Jul 26. doi: 10.1002/jmv.24642.
    PubMed     Abstract available


    March 2016
  129. AKHTAR A, Khan AH, Sulaiman SA, Soo CT, et al
    HBV and HIV co-infection: Prevalence and clinical outcomes in tertiary care hospital Malaysia.
    J Med Virol. 2016;88:455-60.
    PubMed     Abstract available


    December 2015
  130. LO G, Sow-Sall A, Diop-Ndiaye H, Mandiouba NC, et al
    Response to comments by Honge et al. on our paper titled "Prevalence of hepatitis B markers in Senegalese HIV-1 infected patients".
    J Med Virol. 2015 Dec 22. doi: 10.1002/jmv.24452.
    PubMed     Abstract available


  131. HONGE BL, Jespersen S, Medina C, Wejse C, et al
    Comment on Lo et al.: Prevalence of hepatitis B markers in Senegalese HIV-1 infected patients.
    J Med Virol. 2015 Dec 22. doi: 10.1002/jmv.24455.
    PubMed     Abstract available


    November 2015
  132. DE ARAUJO MARIZ C, Lopes EP, Ximenes RA, Lacerda HR, et al
    Serological markers of hepatitis B and C in patients with HIV/AIDS and active tuberculosis.
    J Med Virol. 2015 Nov 18. doi: 10.1002/jmv.24432.
    PubMed     Abstract available


    October 2015
  133. FU J, Guo D, Gao D, Huang W, et al
    Clinical analysis of patients suffering from chronic hepatitis B superinfected with other hepadnaviruses.
    J Med Virol. 2015 Oct 28. doi: 10.1002/jmv.24417.
    PubMed     Abstract available


  134. MOUSSA S, Brah S, Parola P, Gerolami R, et al
    Epidemiological, clinical, virological features of hepatitis B newly diagnosed in 2011 in Marseille University hospitals, southeastern France.
    J Med Virol. 2015 Oct 6. doi: 10.1002/jmv.24398.
    PubMed     Abstract available


    July 2015
  135. WANG J, Liu S, Cao Y, Yang L, et al
    Prevalence of Kaposi's sarcoma associated herpesvirus among men attending sexually transmitted infections clinics in Anhui, China.
    J Med Virol. 2015 Jul 3. doi: 10.1002/jmv.24321.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: